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Familial platelet disorder with predisposition to acute myelo-
genous leukemia (FPD/AML) (OMIM #601399) is an autoso-
mal dominant disorder characterized by quantitative and
qualitative platelet defects and an increased risk of AML.
FPD/AML shares phenotypic similarities with Jacobsen syn-
drome; platelet counts show mild to moderate reductions but
are variable between individuals with the same genetic etiology
of disease, and a reduction in dense granule secretion is often
observed as a secondary qualitative abnormality [1]. The major
clinical complication of this disorder, however, is not the
bleeding tendency experienced by some patients, but the pro-
pensity for a proportion of patients to develop myelodysplasia
or leukemia [2].
The molecular genetic cause of FPD/AML was first elucidated
by linkage studies which mapped the underlying genetic defect to
a region on human chromosome 21q [3]. Contained within this
region is the gene encoding the master regulator of hematopoi-
esis, Runt-related transcription factor 1 (RUNX1). Variants have
been identified throughout the coding region of RUNX1 but those
clustered within the region encoding the Runt homology domain
(RHD), which mediates DNA binding and heterodimerization
with core binding factor beta (CBF-β) [4], and are most likely
to be detrimental [5]. RUNX1 mutation can result in haploinsuffi-
ciency of RUNX1, or reduced RUNX1 function as a result of a
dominant-negative effect, that disrupts the formation of com-
plexes with CBF-β, thereby disturbing the regulation of genes
necessary for hematopoietic stem cell (HSC) maintenance,
maturation, and differentiation [6,7].
Over 40 RUNX1 mutations associated with FPD/AML have
been reported in patients to date (Table I, Figure 1). However,
the prevalence of RUNX1 defects is believed to be under-
estimated and as sequencing technologies improve an increas-
ing number of patients are being reported [8,9]. The
mutations reported are predominantly missense and phenoty-
pically platelets from patients present with dense granule
secretion defects and persistence of MYH10 expression
which can be used as a biomarker of genetic variation
[1,10]. It has been suggested that the risk of malignancy is
reduced in those cases having RUNX1 defects that cause
haploinsufficiency when compared to those patients with
dominant-negative RUNX1 defects. Due to the associated pre-
disposition to myeloid malignancy with some variants in
RUNX1, it is critical to establish diagnosis as early as possible
to aid in patient management and guidance.
Main findings
● RUNX1 defects are associated with mild to moderately reduced
platelet counts.
● RUNX1 defects are associated with reduced responses
to several platelet agonists and decreased platelet
secretion.
● RUNX1 missense mutations are almost exclusively located in
the Runt homology DNA-binding domain.
● RUNX1 defects causing haploinsufficiency are thought to be
associated with a lower incidence of myeloid malignancies
when compared to those patients with dominant-negative
RUNX1 defects.
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Table I. RUNX1 variants reported to date in patients with an FPD/AML inherited bleeding disorder. Heterozygous RUNX1 nucleotide changes present
in patients with inherited bleeding and their predicted effects on the resulting RNA or protein are also shown. Genomic variations are numbered
according to positions in the NM_001001890 transcript for RUNX1. The references where they were initially reported is also indicated.
Genomic variation Protein effect Variation type References
c.16 G>A p.D6N Missense [9]
c.82dup888 p.A28GfsX83 Insertion [11]
c.236 G>A p.W79X Nonsense [1]
c.239 G>A p.R80H Missense [8]
c.247 A>G p.K83E Missense [12]
c.270+1G>T Splicing [1,9]
c.271-1G>T Splicing [3]
c.295 G>C p.D99H Missense [11]
c.319 G>C p.A107P Missense [2]
c.322 G>A p.G108S Missense [9]
c.361_368delACCGCAGC p.T121HfsX9 Deletion [8,13]
c.386 C>A p.A129E Missense [8,14]
c.415 C>T p.R139X Nonsense [15]
c.416 G>A p.R139Q Missense [3]
c.426delA p.Ser145AfsX4 Deletion [16]
c.427 G>A p.G143R Missense [17]
c.427+1G>T Splicing [1]
c.428+3delA p.R135fsX177 Splicing [12]
c.505 A>G p.T169A Missense [9]
c.506 C>G p.T169R Missense [8]
c.511 G>T p.D171Y Missense [17]
c.512 A>T p.D171V Missense [9]
c.520 C>T p.R174X Nonsense [3]
c.521 G>A p.R174Q Missense [3,8]
c.529 C>T p.R177X Nonsense [3]
c.530 G>A p.R177Q Missense [8,9,14]
c.568 G>A p.G190R Missense [18]
c.654delC p.T219RfsX8 Deletion [19]
c.703 C>T p.Q235X Nonsense [17]
c.707delC p.P236LfsX48 Deletion [20]
c.780 C>A p.Y260X Nonsense [12]
c.786delA p.S263PfsX21 Deletion [21]
c.877 C>T p.R293X Nonsense [11]
c.906delG p.F303SfsX264 Deletion [22]
c.918_922dup p.Q308RfsX261 Insertion [8,14]
c.1007_1013delGCATCGG p.G336AfsX229 Deletion [11]
c.1011delC p.I337MfsX230 Deletion [8]
c.1082 C>A p.S361X Nonsense [23]
Figure 1. Schematic showing the protein location of all previously published variants within RUNX1 which are implicated in FPD/AML. The Runt-
homology DNA-binding domain spanning amino acids 49 to182 and the Activation domain spanning from amino acid 243 to 371 is also displayed.
Alterations are numbered according to positions in the NM_001001890 transcript for RUNX1.
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